ArticleArchives of virology2026
Isolation, characterization and evaluation of a novel phage against Elizabethkingia anophelis.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The rise of multidrug-resistant Elizabethkingia anophelis (E. anophelis) presents a significant public health challenge. Here, we report the isolation, morphological and biological characterization, and genomic analysis of a novel lytic bacteriophage, XANYB1, targeting E. anophelis. XANYB1 was isolated from hospital wastewater in Xi’an, China, using a clinical strain as the host. Transmission electron microscopy revealed that XANYB1 belongs to the order Caudoviricetes, featuring icosahedral heads and long, non-contractile tails. Whole-genome sequencing showed very low similarity to known phages, confirming XANYB1 as a novel bacteriophage. The optimal multiplicity of infection (MOI) was determined, and one-step growth curve analysis indicated a latent period of 30 min and a lysis period of approximately 40 min. XANYB1 remained stable across a broad pH range (3–11), at temperatures up to 50 °C, and in the presence of up to 5% chloroform. Host range analysis showed that XANYB1 lysed 5 of 14 clinical E. anophelis isolates. In a mouse sepsis model, XANYB1 exhibited effective in vivo antimicrobial activity, highlighting its potential as a therapeutic candidate. These findings support the application of XANYB1 in phage therapy against multidrug-resistant E. anophelis infections.
Indexed as
Identifiers
41729322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.